

101573868

AP20 Rec'd PCT PTO 29 MAR 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.: Based on PCT/JP2004/014475  
Filed: Intl. Filing 01 OCT 2004  
1<sup>st</sup> Inventor: T. ASAKAWA  
For: Agent for Treating Diabetes  
Atty. Dkt. No. 3197 USOP

Art Unit: tba  
Examiner: tba  
Allowed:  
Batch:  
Paper No.:

**Information Disclosure Statement**

MAIL STOP PCT  
P.O. Box 1450  
Commissioner for Patents  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, 1.97 and 1.98, Applicants request consideration of the references listed on the attached Forms PTO/SB/08A and PTO/SB/08B. A legible copy of each listed reference is herewith being provided to the Examiner.

This Information Disclosure Statement is being submitted within 3 months of the filing date of the above-identified application, and before the mailing date of the first Office Action on the merits, thus, no certification or fee is required.

Applicants respectfully request that the listed documents be considered by the Examiner and formally be made of record in the present application and that an initialed copy of the attached forms be returned in accordance with MPEP §609.


Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call Applicants' attorney.

Dated: 3/28/06

(847) 383-3372  
(847) 383-3391

Takeda Pharmaceuticals North America, Inc.  
Intellectual Property Department  
475 Half Day Road  
Lincolnshire, IL 60069 USA

Respectfully submitted,



Mark Chao, Ph.D., Reg. No. 37,293  
Elaine M. Ramesh, Ph.D., Reg. No. 43,032  
Attorney for Applicants  
Customer No. 23115

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**(Use as many sheets as necessary)**

Sheet	1	of	2
-------	---	----	---

**Complete if Known**

Application Number	Based on PCT/JP2004/014475
Filing Date	Intl. Filing 01-OCT-2004
First Named Inventor	T. Asakawa
Art Unit	tba
Examiner Name	tba
Attorney Docket Number	3197US0P

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.**

1P20B331PCT/PTO 18 MAR 2006

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	Based on PCT/JP2004/014475
		Filing Date	Intl. Filing 01 OCT 2004
		First Named Inventor	T. Asakawa
		Art Unit	tba
		Examiner Name	tba
Sheet 2	of 2	Attorney Docket Number	3197US0P

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A2	J. LARSEN, MD., et al., "Glucagon-Like Peptide-1 Infusion Must be Maintained for 24 h/day to Obtain Acceptable Glycemia in type 2 Diabetic Patients Who are Poorly Controlled on Sulphonylurea Treatment", Diabetes Care, (August 2001), 24(8): 1416-1421	
	A3	M.A. NAUCK, MD., et al., "Influence of Glucagon-Like Peptide 1 on Fasting Glycemia in Type 2 Diabetic Patients Treated with Insulin After Sulfonylurea Secondary Failure", Diabetes Care, (November 1998), 21(11): 1925-1931	
	A4	V. TRISCHITTA, et al., "Comparison of Combined Therapies in Treatment of Secondary Failure to Glyburide", Diabetes Care, (April 1992), 15(4): 539-542	
	A5	G. FANGHANEL, MD., et al., "Metformin's Effects on Glucose and Lipid Metabolism in Patients with Secondary Failure to Sulfonylureas", Diabetes Care, (November 1996), 19(11): 1185-1189	
	A6	H. KIYONO, et al., "Analysis of Functional Relation of Pancreatic Beta-Cell ATP-Sensitive K <sup>+</sup> Channels and Sulfonylurea Receptor, and Development of Oral Antidiabetic Drug Based on New Action Mechanism", Suzuken Memorial Foundation, (2001), pages 147-149, English Translation attached.	✓
	A7	K. YAMADA, "Appropriate Use and Combined Use of Oral Hypoglycemic Agents, (2002), Vol. 36, pp. 292-296, English Translation of Tonyobyogaku no Shinpo attached.	✓
	A8	J. KAN, et al., "The Effect of Ultra-Rapid-Acting Insulin Secretagogue, Nateglinide (Na), in Patients with Type 2 Diabetes That Seems to Be Secondary Ineffectiveness of SU Drugs", The Journal of the Japan Diabetic Society, (2000), 43 (Supple. 1), p. S-120, English Translation attached.	✓
	A9	K. MIMURA, et al., "Experience of Use of Rapid-Acting Postprandial Hypoglycemic Drug (Nateglinide) in Type 2 Diabetic Patients Who Showed Secondary Effectiveness of Sulfonylurea Drugs", Nippon Taishitsugaku Zasshi, (2001), 63(1-2): 52; English Translation attached.	✓
	A10	Y. KITAHARA, et al., "A Rapid-Onset/Short-Duration Insulin Secretagogue as a Physiologic Postprandial Blood Glucose Regulator", Saibo (Cells), 2000, 32(12): 480-483; English Translation Attached	✓

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.